Researchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimer’s ...

Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

Add Yahoo as a preferred source to see more of our stories on Google. An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to ...

Clumps or plaques of the protein beta-amyloid in the brain are a hallmark of a type of dementia called Alzheimer’s disease. When beta-amyloid plaques form, they disrupt communication between nerve ...

A new Alzheimer's treatment side effect that results in brain swelling may have an upside, according to a new study from Houston Methodist Research Institute. The research finds that beta amyloid—a ...

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. | A new entrant in the race to shepherd antibodies for Alzheimer’s disease across ...

While physicians and scientists have long known that Alzheimer's disease involves the buildup of toxic protein fragments in ...

In the quest to cure Alzheimer's, the protein known as beta-amyloid has long taken center stage, driving development of a long list of drugs aimed at breaking up amyloid plaques in the brain.

Scientists have made a breakthrough in understanding how Alzheimer’s disease develops, and a decades-old drug could be the ...

Researchers at Karolinska Institutet have identified two specific receptor proteins in the brain that, when activated, boost the organ’s built-in ability to break down the amyloid-beta plaques ...

In the 1980s, researchers studying the autopsied brains of people with Alzheimer’s discovered that they were clogged with sticky plaques made from beta amyloid proteins and toxic tangles made of a ...